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ABSTRACT 
 
Background: Lung cancer remains the leading cause of cancer mortality with relatively few 
prognostic biomarkers. We investigated associations with overall survival for telomere length (TL) 
and genetic variation in chromosome 5p15.33, an established telomere maintenance locus.  
Methods: Leukocyte TL was measured after diagnosis in 807 non-small cell lung cancer (NSCLC) 
patients from the Princess Margaret Cancer Center in Toronto and assessed prospectively in 767 
NSCLC cases from the Copenhagen City Heart Study and the Copenhagen General Population 
Study. Associations with all-cause mortality were tested for 723 variants in 5p15.33, genotyped in 
4672 NSCLC cases.  
Results: Short telomeres (10th percentile) were associated with poor prognosis for 
adenocarcinoma in both populations: TL measured 6 months after diagnosis (hazard ratio (HR) = 
1.65, 95% confidence intervals (CI): 1.04-2.64) and for those diagnosed within 5 years after blood 
sampling (HR=2.42, 1.37-4.28). Short TL was associated with mortality in never smokers with 
NSCLC (HR=10.29, 1.86-56.86) and adenocarcinoma (HR=11.31, 1.96-65.24). Analyses in 
5p15.33 identified statistically significant prognostic associations for rs56266421-G in LPCAT1 
(HR=1.86, 1.38-2.52, P=4.5×10-5) in Stage I-IIIA NSCLC, and for the SLC6A3 gene with OS in 
females with NSCLC (P=1.6×10-3).  
Conclusions: Our findings support the potential clinical utility of TL, particularly for 
adenocarcinoma patients, while associations in chromosome 5p15.33 warrant further exploration. 
Impact: This is the largest lung cancer study of leukocyte TL and OS, and first to examine the 
impact of the timing of TL measurement. Our findings suggest that extremely short telomeres are 
indicative of poor prognosis in NSCLC. 
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INTRODUCTION 
Lung cancer is the leading cause of cancer mortality, accounting for 19.4% of all deaths among 
cancer patients, with an estimated 5-year survival rate of 15% (1,2). Non-small cell lung cancer 
(NSCLC) accounts for 80-85% of lung cases, and is less aggressive than small cell lung carcinoma 
(SCLC), which has a 5-year survival rate of 6.3% (3). The prognosis of NSCLC patients with 
resected tumours varies drastically by stage, with 5-year survival estimates ranging from 73% to 
25% for Stage IA and IIIA, respectively (4). However, only 16% of patients present with the most 
localized disease, and for the majority of NSCLC cases treatment with platinum-based 
chemotherapy brings modest benefits (3,4). Despite the success of targeted therapies for 
epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) 
rearrangements, the prevalence of actionable molecular targets remains low (5). The present study 
aims to contribute to the identification of prognostic biomarkers in lung cancer by investigating the 
association with overall survival for leukocyte telomere length and genetic variation in chromosome 
5p15.33, which includes the telomerase reverse transcriptase (TERT) gene.   
Telomeres consist of tandem repeats of the TTAGGG sequence, which prevent chromosome ends 
from being perceived as DNA breaks and engaging unwarranted DNA damage repair mechanisms 
(6,7). Human telomeres lose between 50 and 200 base pairs with each replication, and 
progressively erode until senescence or apoptosis occurs (6,7). Although telomere attrition can be 
countered by telomerase, which synthesizes de novo TTAGGG repeats, it is not expressed in most 
normal somatic tissues (8). In contrast, telomerase is overexpressed in 85–90% of tumours, which 
is an important step for the immortalization and continued proliferation of cancer cells (9,10). In 
addition to TERT, which is critical for the functionality of telomerase and maintenance of telomeres 
(11,12), the 5p15.33 region also includes CLPTM1L (cleft lip and palate-associated 
transmembrane 1 like protein), which plays a role in cisplatin-induced apoptosis (13). Together 
these genes denote an established cancer susceptibility locus in 5p15.33 for lung and other 
cancers (14,15). Beyond its canonical telomere-related functions, TERT may also potentiate cell 
proliferation by activating EGFR signaling (16,17).  
In contrast to lung cancer susceptibility, consistent evidence linking 5p15.33 variants to patient 
outcomes has been lacking (18-20). Generally, the overlap between loci influencing lung cancer 
susceptibility and survival has been limited, and few prognostic variants have been identified in 
genome-wide scans and candidate gene approaches (19-21). The apparent lack of associations 
may be due to inadequate statistical power and heterogeneity between patient populations, and it 
is also possible that less common variants may have been overlooked in previous studies that have 
selectively examined prognostic associations for common lung cancer susceptibility variants.  
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Telomere length (TL) has long been an active area of clinical research, with ongoing efforts to 
develop cancer therapeutics targeting telomerase. However, the findings of epidemiological studies 
to date have been inconsistent, partly due to differences in patient populations and tissues in which 
TL was measured. Most studies of lung cancer have examined telomere alterations in tumour 
tissue, with only one analysis of leukocyte TL observing an inverse relationship with mortality (22). 
It appears that shorter TL in tumour tissue may be a marker of poor prognosis, but evidence for the 
clinical utility of leukocyte TL remains sparse (18). In particular, it remains unclear whether telomere 
status observed at the time of clinical presentation contributes useful prognostic information.  
We present two complementary survival analyses of leukocyte TL, its genetic determinants, and 
genetic variation in the 5p15.33 region. First, we assessed the prognostic potential of leukocyte TL, 
measured at two time points: at the time of lung cancer diagnosis in a cohort from the Princess 
Margaret Cancer Center in Toronto, and prior to cancer diagnosis in two population-based cohorts, 
the Copenhagen City Heart Study (CCHS) and the Copenhagen General Population Study (CGPS) 
(22,23). Next, we investigated associations with overall survival in chromosome 5p15.33, including 
rare variants previously identified through deep sequencing (24,25), in 4672 NSCLC cases from 
the OncoArray collaboration (26). Since mechanisms of cancer development and progression may 
be distinct, we extended the scope of our investigation beyond established susceptibility genes, 
TERT and CLPTM1L, to provide a more comprehensive analysis of the 5p15.33 region. Second, 
we examined prognostic associations between genetic determinants of TL and mortality in the 
OncoArray NSCLC population. In addition, to link the two approaches, we investigated whether the 
TL prognostic effect on lung cancer was modified by 5p15 genetic variants. 
MATERIALS & METHODS 
Study Populations 
Telomere Length 
TL was measured in 1127 lung cancer cases from the Mount Sinai Hospital-Princess Margaret 
Cancer Centre Case Control Study (MSH-PMH). Eligible patients were recruited from the Princess 
Margaret Cancer Center in Toronto between 2006 and 2013, and included individuals older than 
18 years of age, with a histologically confirmed, incident lung cancer diagnosis. Blood samples 
were collected at enrolment or the next earliest clinic visit (median lag time: 27 days after 
diagnosis). Information on clinical characteristics and vital status were extracted from electronic 
medical records and the Ontario Cancer Registry. Since TL can be affected by a number of factors 
following cancer diagnosis (27,28), patients who provided blood samples more than 1 year after 
diagnosis were considered ineligible, leaving a total of 888 cases (807 NSCLC). The population for 
the main association analyses was further restricted to 823 patients (745 NSCLC) with DNA 
collected within 6 months of diagnosis. 
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To assess whether pre-diagnostic TL is associated with lung cancer prognosis, 923 incident lung 
cancer cases were identified in the CCHS, enrolled between 1991 and 1994, and the CGPS, 
enrolled between 2003 and 2012. Both studies have been described previously (22,23,29). Briefly, 
participants completed questionnaires, underwent a physical examination, and provided blood 
samples at enrollment. Diagnoses of invasive cancer, with corresponding dates and disease stage, 
were obtained from the national Danish Cancer Registry, which identifies >98% of all cancers in 
Denmark (30). Vital status and date of death was obtained from the Danish Civil Registration 
system, which is 100% accurate. 
In order to contrast TL associations with prognosis, and distinguish from the effects of aging, we 
conducted a separate analysis of TL and mortality in 2905 controls without lung cancer selected 
from the CCHS and CGPS, matching on birthdate, date of blood sample collection, sex, and 
cumulative smoking in pack-years. The median difference between the birthdate in cases and their 
matched controls was 4.7 months, with 75% of controls having a birthdate within 1 year of the index 
lung cancer case, and 88% within 2 years. Eligible controls were not diagnosed with lung cancer 
at enrolment or during follow-up, but other cancers may have occurred.  
TL was measured in DNA isolated from peripheral blood leukocytes using previously described 
quantitative polymerase chain reaction (qPCR) assays performed in Toronto (25) and Copenhagen 
studies (29). This method expresses relative TL as the T/S ratio between telomere (T) repeat copy 
numbers and single gene (S) copy numbers (details in Supplementary File). 
Genetic variants in chromosome 5p15.33 
In addition to Toronto MSH-PMH study, lung cancer patients from the following five studies were 
included: the Harvard Lung Cancer Susceptibility (HLCS), Cáncer de Pulmón en Asturias (CAPUA), 
the University of Texas MD Anderson Cancer Center (MDACC) lung cancer study, the Liverpool 
Lung Project (LLP), and the Carotene and Retinol Efficacy Trial (CARET). All patients were incident 
cases with histologically confirmed lung cancer. Detailed descriptions of participant recruitment and 
endpoint ascertainment have been previously published for the HLCS (31), MDACC (21), CAPUA 
(32), LLP (33), and CARET (34) studies. All studies were approved by research ethics review 
boards at the involved institutions and informed consent was obtained for all participants. 
Descriptions of the genotyping and quality control methods for OncoArray data have been 
previously published (26). Custom content for the 5p15.33 region included variants identified 
through a targeted deep sequencing of 288 independent lung cancer case-control pairs (24). 
Analyses were restricted to individuals of ≥80% European ancestry (26). Variants were filtered to 
retain those with a minor allele frequency (MAF) of 0.001 or greater in the entire OncoArray lung 
cancer dataset, even if study-specific MAF was lower. A total of 723 variants (43 
insertions/deletions), were analyzed. The overall genotyping rate was 0.9977.   
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Statistical Analysis 
For individuals in the Toronto study, follow-up time was calculated from the date of diagnosis to 
date of death, or date of last visit if no death occurred prior to January 17, 2017. For individuals in 
the CGPS and CCHS, follow up time was calculated from the date of diagnosis to date of death, or 
March 22, 2017, whichever came first. The end point for all analyses was death from any cause, 
with patients considered censored if no death occurred within 5 years of follow-up time. Cox 
proportional hazards regression was used to estimate the hazard ratios (HRs) and corresponding 
95% confidence intervals (CIs) for all-cause mortality. All analyses were adjusted for the following 
variables of prognostic significance: disease stage (early: Stage I-IIIA; advanced: Stage IIIB-IV), 
age at diagnosis, sex, and cigarette pack-year categories: 0 (never smokers with fewer than 100 
lifetime cigarettes), >0 to 20, >20 to 40, and >40.  
Violation of the proportionality assumption was assessed by examining the association between 
standardized Schoenfeld residuals and time, and by plotting -ln(-ln(survival) against ln(analysis 
time). No major violations were detected. Associations were further refined in analyses stratified by 
lung cancer histology and established prognostic factors.  
Leukocyte Telomere Length  
TL was analyzed as a continuous and dichotomous variable. To facilitate comparison between 
studies, T/S ratio values were converted to normalized Z-scores in each study. Short TL was 
defined as length in the 10th percentile (Z ≤ -1.28) and the comparison group consisted of TL >10th 
percentile. In addition to standard prognostic covariates, Cox models were also adjusted for body-
mass index (BMI) categories corresponding to normal weight (18.5 to <25), underweight (<18.5), 
overweight (25 to <30), obese (≥30), and unknown. To account for the number of comparisons 
conducted across strata defined by histology, sex, and smoking status, we also present false 
discovery rate (FDR) q-values.  
Cox regression models in the Copenhagen study population were further adjusted for the time 
elapsed between blood sample collection and lung cancer diagnosis, and qPCR calibrator lot 
number, since percentiles were calculated separately for each lot. For comparative analyses of 
mortality in controls without lung cancer, follow-up time started from the date of lung cancer 
diagnosis in the matched case. Heterogeneity of associations was assessed using the likelihood 
ratio test p-value for comparing nested models with and without an interaction term between case-
control status and TL.  
To further characterize how the timing of TL measurement, analyses of pre-diagnostic TL in the 
Copenhagen cohort were restricted to lung cancers diagnosed within 5 years of blood sample 
collection, since only 6% of cases occurred within the first year.  
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Genetic variants in chromosome 5p15.33 
Single-variant analyses and regional, gene-based analyses were carried out to explore predictors 
of survival in chromosome 5p15.33. For each variant, Cox models were fit to the number of copies 
of the minor allele, assuming a log-additive genetic model with 1 degree of freedom. To achieve 
sufficient power for rare variants in subgroup analyses, individual OncoArray studies were pooled. 
In addition to prognostic factors, study-specific analyses were adjusted for 5 genetic ancestry 
principal components (PCs), and pooled analyses were adjusted for 10 PCs. 
For NSCLC, fixed effect meta-analysis was conducted using the R package meta (http://cran.r-
project.org/web/packages/meta/). Heterogeneity across studies was assessed with the Cochran Q 
test (Phet) and I2. Cox models for pooled analyses incorporated a frailty term for study to account 
for heterogeneity between the study populations and non-independence in survival outcomes 
between patients from the same center. The estimated number of effective independent tests (35) 
was applied into the Bonferroni correction formula to determine the significance threshold for single 
variant analysis. The significance threshold was set at P<1.6×10-4 based on 306 independent tests. 
The level for suggestive associations was set at one order of magnitude higher (P<1.6×10-3). 
Gene-level tests were conducted using Cox SKAT-LRT (36). All variants in the 5p15.33 target 
region were assigned to mutually exclusive sets, based on RefSeq genes downloaded from the 
UCSC Genome Browser and GENCODE version 13, implemented using HaploReg v4.1 (37) . Each 
study was analyzed separately, adjusting for appropriate covariates. Single-variant test statistics 
were aggregated by gene and combined across studies using Cox SKAT-LRT and meta-analysis 
implemented within the R package seqMeta (http://cran.r-project.org/web/packages/seqMeta/). 
Associations with P <2.5×10-3 were considered statistically significant after Bonferroni correction 
for 5 genes tested in four NSCLC subgroups.  
RESULTS 
Leukocyte Telomere Length 
Demographic and clinical characteristics of the Toronto MSH-PMH participants are presented in 
Table 1. Median survival time (MST) was 26.2 months (95% CI: 22.7-30.1) for the MSH-PMH cases, 
29.4 months (95% CI: 25.4 - 36.9) for 807 NSCLC and 12.3 months (95% CI: 10.3-17.3) for 74 
SCLC patients. The mean age at diagnosis was 67 years and was negatively correlated with TL 
(Pearson’s r = -0.25, P=6.4×10-14). Over half the patients (57.1%) were diagnosed with early stage 
disease. Several prognostic variables were associated with TL (Table 1), including stage 
(P=4.5×10-3), histology (P=1.8×10-3), and smoking status (P=1.5×10-3). Patients with 
adenocarcinoma and never smokers were characterized by longer leukocyte TL. EGFR mutation 
and ALK translocation status was ascertained in 58 NSCLC patients. Mean TL was significantly 
longer in the patients with EGFR mutation positive (n=26) or ALK rearranged tumours (n=3), when 
compared to the 29 non-EGFR/non-ALK patients (P=1.6×10-3).  
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Baseline characteristics of the Copenhagen cohorts are presented in Supplementary Table S1. 
Most of the lung cancer cases (91.1%) were over 60 years of age. Lung cancer cases diagnosed 
in Copenhagen were predominantly smokers (95.4%), and 50.9% presented with metastatic 
disease (Stage IV) at diagnosis. Information on somatic mutation status was not available in these 
cohorts. 
Telomere Length Measured At The Time of Diagnosis 
In the Toronto MSH-PMH study, survival outcomes were examined in 823 patients with DNA 
samples collected up to 6 months following diagnosis (Table 3). Among the 745 NSCLC cases, 
short leukocyte TL (≤10th percentile) was not associated with 5-year all-cause mortality (HR=1.16, 
95% CI: 0.83-1.63). Compared to patients with long TL, short TL was associated with a higher 
mortality risk in females with NSCLC (HR=1.88, 1.11-3.17; n=358), but not in males (HR=0.93, 
0.59-1.33). A significant association with poor prognosis was observed among never smokers with 
short TL (HR=10.29, 1.86-56.86; qFDR<0.05). 
In histology-specific analyses, short TL was associated with an increased mortality risk in 459 
patients with adenocarcinoma (HR=1.65, 1.04-2.64). The magnitude of this association was larger 
in females (HR=2.54, 1.20-5.38, n=248) and never smokers with short TL (HR=11.31, 1.96-65.24; 
qFDR<0.05, n=77). No associations with prognosis were observed for patients with squamous cell 
carcinoma (HR=0.69, 0.33-1.45) and SCLC (HR=0.62, 0.26-1.45). Association estimates for short 
TL could not be reliably estimated in never smokers with squamous carcinoma (8 cases) and in 
strata defined by EGFR or ALK mutation status (short TL: n=1). 
When analyzing TL values as continuous, we observed decreased mortality in females with NSCLC 
(HR=0.81, 0.67-0.98) and adenocarcinoma (HR=0.72, 0.56-0.93) per unit increase in the 
standardized Z-score (Supplementary Table S2). Relative TL was not associated with survival in 
strata defined by EGFR or ALK status. Deviations from the proportionality assumption (p<0.05) 
were not observed for either TL metric. 
Sensitivity analyses using less restrictive selection criteria, including cases with DNA obtained up 
to 12 months following diagnosis (807 NSCLC), resulted in a similar pattern of associations, 
although the HR estimates were attenuated (Supplementary Table S3). 
Pre-Diagnostic Telomere Length 
Association between TL measured prior to cancer diagnosis and all-cause mortality in the CCHS 
and CGPS are presented in Table 4 (continuous TL in Supplementary Table S4). Among 767 
NSCLC cases, short TL (≤10th percentile) at cohort entry (baseline) was associated with an 
increased 5-year mortality risk (HR=1.52, 1.18-1.95; qFDR<0.05), particularly in females (HR=1.61, 
1.11-2.35, qFDR<0.05; n=361). In histology-specific analyses short TL was significantly associated 
with mortality for adenocarcinoma (HR=1.48, 1.01-2.16). No significant associations were found for 
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squamous carcinoma (HR=1.45, 0.94-2.25) and SCLC (HR=1.42, 0.74-2.74). In matched controls 
without lung cancer short TL was not associated with all-cause mortality.  
Next, we examined associations with TL measured more proximally to lung cancer diagnosis (Table 
4). Among lung cancers diagnosed within 5 years after blood sampling, short telomeres were 
associated with poor prognosis for lung cancer overall (HR=1.89, 1.34-2.66) and all NSCLC 
subtypes, including adenocarcinoma (HR=2.42, 1.37-4.28, qFDR<0.05). A statistically significant 
association between short TL and survival observed in females (HR=4.06, 2.08-7.92; qFDR<0.05), 
but not in males with NSCLC (HR=1.37, 0.82-2.28). In contrast, short TL was not associated with 
mortality in controls matched to cases with NSCLC (HR=0.68, 0.40-1.16) or adenocarcinoma 
(HR=0.70, 0.30-1.63). Significant interactions between TL and case-control status on overall 
survival was observed for NSCLC (P=0.01) and adenocarcinoma (P=0.02), suggesting the 
presence of effect heterogeneity in these subgroups. Analyses stratified by smoking status were 
not pursued due to the high prevalence of current or former smoking (95.4%) in this population.  
Genetic variants in chromosome 5p15.33 
Genetic association analyses were based on a pooled sample of 4672 NSCLC cases from six 
studies, including 1149 from the Toronto MSH-PMH study (Table 2; Supplementary Figure 2). 
Adenocarcinoma was the most common histology, with 2717 cases (58.2%), followed by squamous 
carcinoma with 1406 cases (30.1%). Of the 723 variants analyzed in chromosome 5p15.33, none 
were associated with overall survival in NSCLC at P value of <1.6×10-4, but an indel in LPCAT1, 
Chr5:1463124-TA, was suggestively associated (HR=2.19, 95% CI: 1.46-3.32, P=1.8×10-4; 
MAF=0.004; I2=0.45, Phet=0.06; Figure 1A, Supplementary Figure 3). A region of high linkage 
disequilibrium (LD) between TERT and CLPTM1L (Figure 1B) included a variant suggestively 
associated with 5-year survival in adenocarcinoma patients (rs4975616-G: HR=1.14, 1.06-1.22, 
P=6.6×10-4; MAF=0.38), with another suggestive signal observed in SLC6A3 (rs2617606-A: 
HR=1.66, 1.27-2.18, P=2.1×10-4; MAF=0.016). For squamous carcinoma (Figure 1C), a significant 
association was observed for Chr5:1346940-C (HR=1.92, 1.37-2.70, P=1.6×10-4; MAF: 0.015).  
Stratifying by disease stage revealed a significant association with mortality for an LPCAT1 variant 
in patients with early stage disease (Figure 1D: rs56266421-G HR=1.86, 1.38-2.52, P=4.5×10-5; 
MAF=0.015). Sex-stratified analyses identified a suggestive signal in SLC6A3 for females (Figure 
1F), denoted by Chr5:1439260-G (HR=4.82, 2.12-10.95, P=1.8×10-4; MAF=0.001). Gene-based 
Cox SKAT-LRT analyses supported the association pattern emerging in the single-variant analysis 
(Table 5). Variants in SLC6A3 were significantly associated with overall survival in females with 
NSCLC (P=1.6×10-3) and remained significant after restricting to rare variants with MAF≤0.01 
(P=1.4×10-3).  
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Integrative Analysis of 5p15.33 and Telomere Length 
To integrate telomere and genetic association analyses, we investigate whether any 5p15.33 
variants modify the prognostic association between TL and NSCLC survival in a subset of 705 
MSH-PMH patients that have both TL and OncoArray data. We examined interaction between short 
TL and rs2736100 (TERT), a variant known to be associated with leukocyte TL in cancer-free 
controls. There was some evidence of effect modification observed for rs2736100 (interaction 
P=0.037). In stratified analyses short TL was associated with increased NSCLC mortality, and 
reduced median survival (Supplementary Figure 4), in the rs2736100-CC group (adjusted 
HR=2.28, 1.20-4.37), but not in patients with rs2736100-CA/AA genotypes (adjusted HR=1.16, 
0.74-1.68).     
In addition to effect modification, we investigated whether established telomere loci were 
associated with mortality: ACYP2 (rs10165485-G), PXK (rs6772228-G), TERC (rs10936599-A), 
TERT (rs2736100-A), NAF1 (rs11100479-G), OBFC1 (rs9420907-A), ZNF676 (rs10419926-C), 
and RTEL1 (rs755017-G). Adjusted HRs were estimated for the allele associated with decreasing 
TL in 6 OncoArray populations. Generally, regions involved in telomere maintenance did not seem 
to have prognostic significance (Supplementary Figure 5). A linear combination of all TL-associated 
loci was not significantly associated with mortality for NSCLC overall (HR=1.01. 0.99–1.04, p=0.34) 
or any histological subtypes. 
DISCUSSION 
This comprehensive analysis of two large, well-characterized lung cancer populations suggests 
that short leukocyte TL may serve as a marker of poor prognosis in NSCLC, particularly for 
adenocarcinoma. This association was confirmed in two independent study populations, with 
telomere length assessed at different time points. Other notable findings include the increased 
mortality risk observed in females and never smokers with short telomeres. However, as 
adenocarcinoma is the predominant NSCLC subtype in females and never smokers, these findings 
may primarily reflect a histology-specific relationship.  
Other findings of interest include an observation that was previously reported (38) of longer 
leukocyte TL in patients with EGFR or ALK mutations. Although mutation status did not modify the 
association between TL and survival, statistical power was limited in this subgroup. Our integrative 
analyses suggest that the prognostic associations observed for leukocyte TL may be modified by 
rs2736100 (TERT) genotype. The adverse impact of short TL on mortality was significant only in 
patients with a genetic predisposition to longer telomeres (rs2736100-CC). However, genetic 
variants involved in telomere maintenance in 5p15.33 and other regions do not appear to have a 
direct effect on survival. 
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The present study offers novel insight into the role of telomeres in lung cancer survival by examining 
associations with TL observed at the time of diagnosis and clinical presentation. Our findings are 
consistent with an earlier analysis of the Copenhagen cohorts by Weischer et al. (22), which 
reported that shortened leukocyte TL, measured at cohort entry, was associated with an increased 
mortality risk in lung cancer patients. In addition to evaluating associations with TL at clinically 
relevant time points, our analysis extends previous work by including a 40% increase in the number 
of lung cancer cases from the Copenhagen population. We also refined prognostic associations by 
clinically distinct subgroups, such as histology, sex, and smoking status. The consistency of 
associations observed in the Copenhagen cohorts and Toronto patients suggests that leukocyte 
TL may capture patient characteristics indicative of prognosis both at the time of disease detection 
and years prior to NSCLC diagnosis. Short TL may be a marker of systemic factors, such as 
impaired immune competence (29,39), inflammation (40), and reduced regenerative capacity (41). 
Therefore, leukocyte TL serves as an integrative biomarker of heritable intrinsic factors, in addition 
to DNA damage accumulated due to hemodynamic, metabolic, and oxidative stressors.  
Short telomeres have also been associated with increased all-cause mortality in the general 
population (23,42). However, the findings of our comparative analysis conducted in matched 
controls demonstrate that associations with survival in lung cancer patients are not indicative of a 
general survival advantage, since controls were carefully selected matching on relevant prognostic 
characteristics. These differences are also unlikely to be caused by selection bias due to the 
exclusion of individuals in poor health, since the control group included participants diagnosed with 
other cancers and medical conditions.  
The results of the genetic association analyses suggest that in contrast to lung cancer risk, few 
prognostic variants are found in the 5p15.33 region. A significant association with survival in early 
stage NSCLC was observed for rs56266421 (LPCAT1), located in a regulatory region enriched for 
enhancer and promoter histone marks in several tissues, including lung (37). Another suggestive 
association was observed in adenocarcinoma patients for rs4975616 (MIR4457), an established 
lung cancer susceptibility locus (14) previously linked to overall and progression-free survival in 
advanced NSCLC (67% adenocarcinoma) (19). Gene-based analyses identified an association 
with mortality in females with NSCLC for the dopamine transporter SLC6A3 gene, which contains 
a number of expression lung quantitative trait loci (43). Dopamine transporters are expressed in 
lung tumour cell lines (44), and functions related to tumour growth inhibition and regulation of 
angiogenesis have been proposed (45,46). Overall, our findings suggest that 5p15.33 genes 
previously implicated in lung cancer susceptibility, such as TERT and CLPTM1L, are less relevant 
for clinical endpoints. Similarly, genetic determinants of TL that exhibit strong associations with 
lung cancer risk, particularly adenocarcinoma (47,48), were not associated with survival outcomes 
in these patients. However, all-cause mortality is a composite outcome that may obscure 
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associations with more specific endpoints, such as a progression free survival and treatment 
response. 
In evaluating the potential clinical implications of this work, several limitations should be 
acknowledged. Firstly, information on cause of death was not available for all studies, which 
precluded an analysis of lung cancer-specific mortality, treating other causes of death as competing 
risks. However, deaths in the majority of patients, particularly with advanced disease, can be 
directly or indirectly attributed to lung cancer. The accuracy of cause of death determination can 
also vary (49), making all-cause mortality an informative, and potentially less biased endpoint.  
Secondly, treatment information was not available for all patient populations. Adjustment for stage 
may partly account for treatment patterns, since early-stage patients are typically eligible for 
surgery, whereas those with locally advanced and metastatic disease tend to receive 
chemotherapy. Thirdly, this analysis did not account for the impact of comorbid conditions on 
survival. Certain chronic conditions, such as congestive heart failure and chronic obstructive 
pulmonary disease, may have an independent effect on survival and contribute to adverse 
outcomes by preventing patients from receiving aggressive lung cancer treatment (50). However, 
this is somewhat mitigated by adjustment for disease stage, since the impact of these conditions 
may predominate in early-stage disease.  
Despite these limitations, this work provides further insight into the potential clinical utility of 
telomere length and genetic variants in 5p15.33. In this large-scale study of well-characterized 
clinical populations, we demonstrated that leukocyte TL predicts survival in NSCLC and 
adenocarcinoma patients, at multiple time points, and this association is unlikely to simply reflect a 
relationship with longevity. Although associations between TL and mortality were also observed in 
never smokers and patients with other NSCLC histology, we urge caution in interpreting these 
associations, particularly findings observed in strata with few individuals.  
The large size of the OncoArray study population enabled a thorough exploration of rare and novel 
variants in an important genetic region. However, even with a sample size of 4672 NSCLC cases, 
this analysis was underpowered for extremely rare variants and heterogeneity between study 
populations may have also reduced power for detecting associations with survival. In summary, 
this study supports the potential of leukocyte telomere length to contribute information that may 
improve prognostic assessment of NSCLC patients. Future studies are needed to validate these 
associations and inform clinically relevant thresholds of telomere attrition.   
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Table 1: Demographic characteristics and clinical features of 888 lung cancer cases with telomere length 
data, expressed as standardized Z-score, in the Toronto Mount Sinai Hospital - Princess Margaret 
Hospital (MSH-PMH) study 
Characteristic N (Deaths) Mean TL (SD) P MST P Log-rank 
Status        
Alive/Censored (%) 420 (47.3)  0.07 (0.99) 0.06   
Deceased  (%) 468 (52.7) -0.06 (1.00)    
Histology        
Adenocarcinoma 501 (219)  0.11 (0.99) 1.8×10
-3
 42.2 2.2×10
-12
 
Squamous carcinoma 167 (94) -0.22 (0.99)  19.9  
Other NSCLC
2
 139 (92) -0.01 (1.01)  18.9  
SCLC 74 (57) -0.15 (0.99)  12.3  
Other
3
 6 (5) -0.43 (0.98)  20.7  
Age at diagnosis        
≤50 years 55 (31)  0.49 (0.87) 3.0×10
-11
 25.4 0.51 
51 to 60 years 163 (81)  0.28 (1.00)  29.3  
61 to 70 years 301 (152)  0.05 (0.95)  27.9  
71 to 80 years 270 (147) -0.67 (1.00)  25.4  
>80 years 99 (57) -0.45 (0.96)  19.7  
Sex        
Males 463 (285) -0.01 (1.00) 0.87 19.1 3.9×10
-8
 
Females 425 (183)  0.01 (1.00)  41.2  
Smoking status        
Never 102 (39)  0.30 (0.96) 1.5×10
-3
 51.2 5.6×10
-3
 
Ever 760 (412) -0.04 (1.00)  24.4  
Former 347 (190) -0.06 (0.99)  24.2  
Current 387 (213) -0.04 (1.00)  22.9  
Missing 9 (17)  0.07 (0.93)  22.2  
Clinical Stage        
NSCLC      29.4  
I 265 (54) -0.08 (0.95) 4.5×10
-3
 - 1.2×10
-64
 
II 78 (19) -0.17 (1.12)  -  
III 200 (123)  0.00 (0.98)  22.9  
IIIA 118 (64)  0.02 (1.00)  27.6  
IIIB 79 (56) -0.04 (0.96)  16.6  
IV 264 (209)  0.18 (1.00)  10.7  
SCLC      12.3  
Limited 25 (13) -0.43 (1.05)  22.4  
Extensive 49 (44) -0.02 (0.95)  10.7  
Mutation status        
Missing or not tested 749 (375) -0.03 (1.00)  25.8  
EGFR
-
 and ALK
-
 29 (18)  0.08 (0.86) 1.6×10
-3
 22.9 2.0×10
-3
 
EGFR
+
 or ALK
+
 29 (12)  0.78 (0.74)  41.3  
ECOG performance status        
0 - Fully active 253 (84)  0.04 (0.97) 0.35 58.3 1.7×10
-23
 
1 340 (190)  0.04 (1.02)  22.9  
  
2 169 (112) -0.06 (1.00)  16.5  
3 67 (51) -0.04 (1.01)  8.2  
4 - Completely disabled 3 (3)  0.72 (0.83)  17.3  
Missing 56 (28) -0.20 (0.95)  37.8  
Body mass index (kg/m
2
)        
Normal: 18.5 to <25  354 (181)  0.08 (1.00) 0.14 25.9 9.0×10
-5
 
Underweight: <18.5 45 (34) -0.23 (1.11)  12.2  
Overweight: 25 to <30 262 (140) -0.07 (1.03)  29.3  
Obese: >30 141 (58)  0.06 (0.98)  39.5  
Missing 86 (55) -0.10 (0.85)  19.0  
Self-reported ethnicity        
Caucasian 842 (449)  0.00 (1.00) 0.25 25.8 0.20 
Other
4
 7 (2)  0.63 (0.81)  -  
Missing 40 (19)  0.01 (0.96)  39.9  
1 
Median survival time (MST) expressed in months 
2 
Includes tumours with adeno-squamous or NSCLC not otherwise specified histology 
3 
Includes tumours of mixed SCLC and NSCLC histology 
4 
Includes individuals with self-reported Asian/Pacific Island, and Latino/Hispanic ethnicity 
Abbreviations: MSH-PMH - Mount Sinai Hospital - Princess Margaret Hospital; NSCLC - Non-small cell lung cancer; 
SCLC - Small cell lung cancer; EGFR - Epidermal growth factor receptor; ALK - anaplastic lymphoma kinase; ECOG 
- Eastern Cooperative Oncology Group 
  
Table 2: Demographic characteristics and clinical features non-small cell lung cancer (NSCLC) patients 
comprising the OncoArray dataset for the analysis of chromosome 5p15.33 variants and overall survival 
Characteristic 
Study 
Total 
HLCS MSH-PMH MDACC CAPUA LLP CARET 
N % N (%) N (%) N (%) N (%) N (%) N (%) 
Status               
Alive/Censored 655 (38.2) 557 (48.5) 410 (58.1) 45 (8.6) 113 (32.2) 43 (18.7) 1823 (39.0) 
Deceased 1058 (61.8) 592 (51.5) 296 (41.9) 479 (91.4) 186 (67.8) 186 (81.2) 2849 (61.0) 
Histology               
Squamous 398 (23.2) 261 (22.7) 196 (27.8) 288 (55.0) 173 (49.3) 90 (39.3) 1406 (30.1) 
Large cell 102 (6.0) 33 (2.9) 5 (0.7) 18 (3.4) 0 (0.0) 20 (8.7) 178 (3.8) 
Adenocarcinoma 1027 (60.0) 757 (65.9) 431 (61.0) 218 (41.6) 165 (47.0) 119 (52.0) 2717 (58.2) 
NSCLC NOS 186 (10.9) 98 (8.5) 74 (10.5) 0 (0.0) 13 (3.7) 0 (0.0) 371 (7.9) 
Age at diagnosis               
Mean (SD) 65.3 (10.8) 66.0 (10.8) 65.3 (9.7) 66.2 (10.6) 67.5 (7.7) 68.7 (5.7) 65.9 (10.2) 
≤50 years 159 (9.3) 91 (7.9) 50 (7.1) 49 (9.4) 2 (0.6) 0 (0.0) 351 (7.5) 
51 to 60 years 379 (22.1) 231 (20.1) 151 (21.4) 105 (20.0) 63 (17.9) 15 (6.5) 944 (20.2) 
61 to 70 years 539 (31.5) 375 (32.6) 284 (40.2) 158 (30.2) 159 (45.3) 119 (52.0) 1634 (35.0) 
71 to 80 years 504 (29.4) 349 (30.4) 188 (26.6) 181 (34.5) 115 (32.8) 93 (40.6) 1430 (30.6) 
>80 years 132 (7.7) 103 (9.0) 33 (4.7) 31 (5.9) 12 (3.4) 2 (0.9) 313 (6.7) 
Sex               
Males 841 (49.1) 576 (50.1) 361 (51.1) 461 (88.0) 203 (57.8) 155 (67.7) 2597 (55.6) 
Females 872 (50.9) 573 (49.9) 345 (48.9) 63 (12.0) 148 (42.2) 74 (32.3) 2075 (44.4) 
Smoking status               
Never 178 (10.4) 122 (10.6) 70 (9.9) 32 (6.1) 73 (20.8) 0 (0.0) 475 (10.2) 
Ever 1517 (88.6) 1014 (88.3) 635 (89.9) 492 (93.9) 278 (79.2) 219 (100) 4165 (89.1) 
Former 967 (56.5) 510 (44.4) 374 (53.0) 223 (42.6) 148 (42.2) 45 (19.7) 2267 (48.5) 
Current 550 (32.1) 478 (41.6) 261 (37.0) 267 (51.0) 126 (35.9) 184 (80.3) 1866 (39.9) 
Missing 18 (1.0) 13 (1.1) 1 (0.1) 0 (0.0) 0 (0.0) 0 (0.0) 32 (0.7) 
Clinical Stage               
I 508 (29.7) 404 (35.2) 263 (37.3) 141 (26.9) 120 (34.2) 44 (19.2) 1480 (31.7) 
II 192 (11.2) 108 (9.4) 117 (16.6) 45 (8.6) 58 (16.5) 23 (10.0) 543 (11.6) 
III 445 (26.0) 295 (25.7) 141 (20.0) 185 (35.3) 67 (19.1) 65 (28.4) 1198 (25.6) 
IIIA 201 (11.7) 164 (14.3) 84 (11.9) 70 (13.4) 36 (10.3) 40 (17.5) 595 (12.7) 
IIIB 244 (14.2) 127 (11.1) 57 (8.1) 115 (21.9) 31 (8.8) 12 (5.2) 586 (12.5) 
IV 537 (31.3) 342 (29.8) 185 (26.2) 152 (29.0) 55 (15.7) 72 (31.4) 1343 (28.7) 
Missing 31 (1.8) 0 (0.0) 0 (0.0) 1 (0.2) 51 (14.5) 25 (10.9) 108 (2.3) 
Total  1713  1149  706  524  351  229  4672  
MST (months) 
29.6 
(26.6 - 32.0) 
35.6 
(31.2 - 40.2) 
42.9 
(37.5 - 60.0) 
9.2 
(8.2 - 10.4) 
28.2 
(21.9 - 37.3) 
12.0 
(9.6 - 14.4) 
26.9 
(25.2 - 28.7) 
 
Abbreviations: HLCS - Harvard Lung Cancer Susceptibility; MSH-PMH - Mount Sinai Hospital - Princess Margaret 
Hospital; MDACC - MD Anderson Cancer Center; CAPUA - Cáncer de Pulmón en Asturias; LLP - Liverpool Lung 
Project; CARET - Carotene and Retinol Efficacy Trial; MST - median survival time  
  
Table 3: Adjusted hazard ratios (HR) for 5-year all-cause mortality comparing short (≤10
th
 percentile) with 
long telomere length (>10
th
 percentile) in lung cancer patients from the Toronto Mount Sinai Hospital - 
Princess Margaret Hospital (MSH-PMH) study, restricted to samples obtained up to 6 months following 
diagnosis 
 N (Deaths) HR
1
 (95% CI) P qFDR 
All lung cancers 823 (438) 1.09 (0.80, 1.47) 0.61 0.67 
Non-small cell lung cancer (NSCLC) 745 (378) 1.16 (0.83, 1.63) 0.38 0.52 
Smoking status       
Never 86 (34) 10.29 (1.86, 56.86) 7.5×10
-3
 0.04 
Ever 639 (332) 1.05 (0.74, 1.49) 0.79 0.79 
Histology       
Adenocarcinoma 459 (206) 1.65 (1.04, 2.64) 0.03 0.08 
Males 211 (117) 1.25 (0.67, 2.33) 0.48 0.59 
Females 248 (89) 2.54 (1.20, 5.38) 0.01 0.06 
Smoking status       
Never 77 (27) 11.31 (1.96, 65.24) 6.7×10
-3
 0.04 
Ever 371 (174) 1.38 (0.84, 2.29) 0.21 0.46 
Squamous cell carcinoma 159 (89) 0.69 (0.33, 1.45) 0.32 0.50 
Small cell lung cancer (SCLC) 71 (54) 0.62 (0.26, 1.45) 0.27 0.50 
1 
Cox models adjusted for age at diagnosis (years), sex, stage (I-IIIA vs. IIIB-IV or Limited vs. Extensive for SCLC), 
cigarette pack-years (0, >0-20, 21-40, and >40), and body mass index (<18.5, 18.5 to <25, 25 to <30, ≥30, unknown) 
  
  
Table 4: Adjusted hazard ratios (HR) for 5-year all-cause mortality comparing short (≤10
th
 percentile) with long telomere length (>10
th
 percentile) in 
lung cancer cases and controls matched to each lung cancer subgroup from the Copenhagen City Heart Study and Copenhagen General 
Population Study, stratified by time elapsed between sample collection for telomere length measurement and lung cancer diagnosis  
 
 
Lung Cancer Cases General Population Controls P for 
Interaction
3
 N  (Deaths) HR
1
 (95% CI) P qFDR N (Deaths) HR
2
 (95% CI) P 
All lung cancers 923 (769) 1.48 (1.18, 1.87) 6.9×10
-4
 0.002 2905 (429) 1.15 (0.87, 1.52) 0.33 0.73 
NSCLC 767 (629) 1.52 (1.18, 1.95) 1.2×10
-3
 0.003 2437 (346) 0.99 (0.72, 1.37) 0.96 0.39 
Histology             
Adenocarcinoma 440 (351) 1.48 (1.01, 2.16) 0.04 0.06 1448 (162) 1.06 (0.66, 1.70) 0.80 0.94 
Squamous 211 (175) 1.45 (0.94, 2.25) 0.09 0.11 653 (120) 1.03 (0.58, 1.81) 0.92 0.86 
Other NSCLC
4
 116 (103) 2.91 (1.50, 5.65) 1.6×10
-3
 0.004 336 (64) 0.86 (0.39, 1.87) 0.70 0.01 
SCLC 156 (140) 1.42 (0.74, 2.74) 0.29 0.31 468 (83) 1.76 (0.98, 3.14) 0.06 0.83 
Diagnosed <5 years after sample collection   
All lung cancers 382 (335) 1.89 (1.34, 2.66) 2.9×10
-4
 0.001 1313 (189) 0.95 (0.62, 1.45) 0.82 0.12 
NSCLC 319 (277) 1.98 (1.37, 2.86) 2.8×10
-4
 0.001 1093 (149) 0.68 (0.40, 1.16) 0.16 0.01 
Males 182 (160) 1.37 (0.82, 2.28) 0.23 0.27 583 (108) 0.62 (0.32, 1.19) 0.15 0.04 
Females 137 (117) 4.06 (2.08, 7.92) 4.0×10
-5
 0.001 510 (41) 0.77 (0.30, 2.01) 0.60 0.33 
Histology             
Adenocarcinoma 170 (145) 2.42 (1.37, 4.28) 2.3×10
-3
 0.005 614 (69) 0.70 (0.30, 1.63) 0.40 0.02 
Squamous 86 (75) 2.19 (1.09, 4.41) 0.03 0.05 281 (54) 1.20 (0.53, 2.70) 0.66 0.77 
SCLC 63 (58) 1.33 (0.45, 3.89) 0.60 0.60 220 (40) 1.88 (0.85, 4.17) 0.12 0.22 
1 
Cox models adjusted for age at diagnosis (years), sex, stage (I-IIIA, IIIB-IV, unknown), cigarette pack-years (0, >0-20, 21-40, >40, unknown), body mass index 
(<18.5, 18.5 to <25, 25 to <30, ≥30, unknown), calibrator lot for the telomere measurement assay, time elapsed between telomere measurement and lung cancer 
diagnosis 
2 
Cox models adjusted for age at diagnosis (years), sex, cigarette pack-years (0, >0-20, 21-40, >40, unknown), body mass index (<18.5, 18.5 to <25, 25 to <30, 
≥30, unknown), calibrator lot for the telomere measurement assay, and time elapsed between blood sample collection and lung cancer diagnosis in the matched 
case 
3 
P-value for interaction between case-control status and telomere length was calculated using the likelihood ratio test comparing nested models with and without 
an interaction term 
Abbreviations: NSCLC - Non-small cell lung cancer; SCLC - Small cell lung cancer
  
Table 5: Gene-level associations with 5-year overall survival based on the Cox SKAT-LRT meta-analysis 
of 6 OncoArray studies. Associations with P <2.5×10
-3
 were considered statistically significant. 
Gene Set 
All variants (N=723) Rare variants: MAF ≤ 0.01 (N=182) 
N  P NSCLC P Adeno P SQC P Females N  P NSCLC P Adeno P SQC P Females 
TERT 119 0.06 0.14 0.03 0.22 48 0.03 0.05 0.02 0.07 
CLPTM1L 58 0.54 0.13 0.14 0.05 15 0.51 0.53 0.12 0.03 
LINC01511 40 0.60 0.91 0.39 0.02 8 0.51 0.88 0.31 0.10 
SLC6A3 144 0.10 4.1×10
-3
 0.56 1.6×10
-3
 50 0.09 3.3×10
-3
 0.93 1.4×10
-3
 
LPCAT1 172 0.09 0.41 0.02 0.13 28 0.05 0.08 0.02 0.31 
 
Abbreviations: NSCLC - Non-small cell lung cancer; MAF - minor allele frequency; SQC - squamous cell carcinoma 
 
  
  
Figure 1: Regional plots of associations with 5-year survival for NSCLC overall, based on a meta-
analysis of 6 OncoArray studies, and pooled Cox regression analyses stratified by histology, sex, and 
disease stage. Linkage disequilibrium is illustrated with respect to the lead variant denoted in purple. The 
threshold for declaring statistical significance (P = 1.6×10
-4
) is indicated by the solid red line, with 
suggestive associations denoted by the dotted red line (P = 1.6×10
-3
). 
 

